SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001640334-21-002755
Filing Date
2021-11-12
Accepted
2021-11-12 16:40:21
Documents
45
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 6-K nymox_6k.htm   iXBRL 6-K 43376
2 QUARTERLY REPORT FOR THE QUARTER ENDED SEPTEMBER 30, 2021 nymox_ex991.htm   iXBRL EX-99.1 490011
3 CEO CERTIFICATIONS nymox_ex992.htm EX-99.2 13567
4 CFO CERTIFICATIONS nymox_ex993.htm EX-99.3 13759
10 nymox_ex991img1.jpg GRAPHIC 5627
  Complete submission text file 0001640334-21-002755.txt   2251167

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA nymox-20210930.xsd EX-101.SCH 35449
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE nymox-20210930_lab.xml EX-101.LAB 137932
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE nymox-20210930_cal.xml EX-101.CAL 30860
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nymox-20210930_pre.xml EX-101.PRE 111614
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nymox-20210930_def.xml EX-101.DEF 50062
11 EXTRACTED XBRL INSTANCE DOCUMENT nymox_6k_htm.xml XML 360951
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669
NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-12033 | Film No.: 211404289
SIC: 2835 In Vitro & In Vivo Diagnostic Substances